Alnylam announces u.s. food and drug administration has granted priority review of the lumasiran new drug application for the treatment of primary hyperoxaluria type 1

Alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the u.s. food and drug administration (fda)

ALNY Ratings Summary

ALNY Quant Ranking